Loading…
Clinical-stage neuroscience biotech using a proprietary prodrug delivery platform for CNS drug candidates.
Clinical-stage neuroscience biotech using a proprietary prodrug delivery platform for CNS drug candidates.
Moat: none
Headquarters: Boston, Massachusetts, US · Employees: 54
Size Seaport Therapeutics (SPTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.15B, the 2162nd largest of 3,117 United States companies the cockpit tracks. Shares closed at $21.50 on 6 Nov 2026.
Performance Over six months the shares gained 34.0%, against -13.4% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 21 in its peer set.
Capital Return on invested capital runs 81.5 points below its cost of capital (19.8% WACC).
Short interest Short interest is 7.0% of the free float (15 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | n/a | -$1.41M | -$214,000 |
| EBITDA | n/a | -$85.9M | -$52.2M |
| Net income | n/a | -$74.9M | -$46.9M |
| Free cash flow | n/a | -$78.3M | -$29.7M |
| Capital expenditure | n/a | $356,000 | $113,000 |
| Total debt | $4.69M | $5.08M | $5.01M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SPTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +20.0% | -4.1% | highest of 21 |
| 6-month return | +34.0% | -13.4% | highest of 21 |
| Distance from 52-week high | -24.2% | -33.8% | 8th highest of 21 |
| ROIC minus cost of capital | -81.5 pp | +0.2 pp | lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Seaport Therapeutics SPTX | United States | $1.15B | +34% | n/a | n/a | n/a | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.15B | -1% | -23% | -131% | 51.0× | n/a | n/a |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.13B | -34% | +32% | 14% | 22.0× | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.13B | -18% | +9% | 28% | 4.6× | 1.5% | +18.7% |
| North China Pharmaceutical 600812.SS | China | $1.17B | -8% | -21% | 5% | 2.5× | 1.4% | -4.2% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1.17B | +28% | +24% | 6% | 6.3× | 16.2% | +19.4% |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.13B | -18% | +17% | 20% | 2.5× | 1.1% | +22.8% |
| Cosmo CMHC.SW | Switzerland | $1.17B | -25% | -45% | -13% | 8.3× | n/a | n/a |
| Vetoquinol VETO.PA | France | $1.17B | +22% | -1% | 15% | 1.6× | -3.0% | +4.2% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.18B | -4% | -9% | 11% | 2.5× | 5.8% | +11.3% |
| GC Biopharma 006280.KS | South Korea | $1.18B | +2% | -3% | 4% | 0.8× | 8.3% | +5.8% |
| ST Pharm 237690.KS | South Korea | $1.12B | -52% | +26% | 18% | 3.8× | n/a | n/a |
| InventisBio 688382.SS | China | $1.19B | -41% | -61% | -563% | 94.5× | 10.4% | -60.6% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.11B | -13% | -7% | 3% | 1.6× | 3.3% | +6.5% |
| Jiuzhitang 000989.SZ | China | $1.19B | -13% | +46% | 19% | 2.6× | -3.7% | -9.0% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.11B | +13% | -28% | 28% | 11.8× | 49.0% | +13.8% |
| Bio-Thera Solutions 688177.SS | China | $1.10B | -14% | +24% | -44% | 7.6× | n/a | n/a |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $1.10B | -51% | +19% | 9% | 4.3× | 13.9% | +4.9% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.10B | -29% | +103% | 24% | 4.3× | 8.6% | -4.5% |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.21B | -8% | -2% | 15% | 4.5× | 4.5% | -1.2% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $1.09B | -15% | -4% | 2% | 1.4× | n/a | n/a |